BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens - EverGlade Consulting

BARDA Antibiotic for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia or Bloodstream Infections Caused by Drug-Resistant Bacteria or Biothreat Pathogens

drug-resistant bacterial infections

The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice (SSN) to gather insights from antibiotic developers working on solutions for drug-resistant bacterial infections. This SSN is part of BARDA’s Antimicrobial Resistance (AMR) Project BioShield, which focuses on understanding the current antibiotic landscape and potentially facilitating future acquisitions to combat hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI).

Overview of Solicitation

BARDA’s SSN is a market research effort intended to collect information on the capabilities and status of antibiotics in development for treatment of drug-resistant infections. This project seeks input from businesses (both small and large) on their products and assesses the potential to expand indications to include biothreat pathogens.

Key Proposal Information

BARDA is specifically interested in:

  • Antibiotic Programs with FDA Progress: Antibiotics targeting HABP, VABP, and BSI that have reached or will reach the end of Phase 2 by May 1, 2025.
  • Biothreat Indications: Products that could potentially address biothreat pathogens (e.g., Yersinia pestis and Bacillus anthracis).
  • Clinical and Manufacturing Details: Information on clinical studies, safety data, manufacturing capacity, and timelines for product availability.
  • Commercialization Strategy: Respondents should detail their strategy for bringing products to market and ensuring sustainability.

Additional Considerations

This SSN emphasizes BARDA’s focus on supporting products with strong domestic manufacturing capabilities. The initiative also includes a clear confidentiality framework, allowing companies to submit proprietary information while protecting intellectual property rights.

Important Deadlines

  • Questions Due: Questions regarding the SSN must be submitted by November 29, 2025, Noon EST.
  • Response Submission: Final responses are due on the same day, November 29, 2025, Noon EST.

If your company has considered applying for BARDA funding, your federal funding journey starts here.

For additional information about EverGlade Consulting, reach out to: [email protected]

Collaborate With Everglade Consulting

EverGlade Consulting is a national consulting firm connecting public sector needs with private sector solutions. We offer services ranging from Pursuit, Proposal, and Post-Award support to comply with federal regulations at agencies including BARDA, ASPR, NIH, DTRA, JPEO, DOD, DOE, and DARPA.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top
Flask with blue light

Webinar: R&D Funding in Life Sciences: What's Ahead in Trump 2.0?

Join us on Jan 15, 2025, at 12:00pm ET for a deep dive into the future of R&D Funding in Life Sciences.